A best evidence topic in cardiac surgery was written according to a structured protocol. The issue was to determine the impact of bridgeto-transplant ventricular assist device support on survival after cardiac transplantation. Altogether 428 papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The treatment options for patients with advanced heart failure or those with deteriorating end-organ function on maximal medical therapy are limited to intravenous inotropes and mechanical assistance with intra-aortic balloon pump (IABP) or ventricular assist device (VAD). Studies exploring the effect of VADs on post-transplant mortality have yielded conflicting results. The Registry of the International Society for Heart and Lung Transplantation continues to identify mechanical support as a risk factor for decreased survival after transplantation. A limitation of this report is that the multivariable adjustment uses variables recorded not at the time of device implant but at the time of transplant. Some of the recipient characteristics thus may be altered by the device implant. Compared with the previous reports the latest data show improvement in post-transplant survival in the recent era. In addition, the excess risk appears to be limited to the early post-transplant period. Experienced centers consistently report outstanding post-transplant results with left ventricular assist device (LVAD) bridging. Of the 12 papers seven showed no difference in survival, and five showed a reduced survival. In the papers showing no difference, one year survival averaged from 85% in supported patients to 87% in non-supported patients. In papers reporting a difference in outcome, one year averaged survival was 74% in LVAD recipients compared to 90% in non-bridged patients. Decreased survival is associated with patients suffering from dilated cardiomyopathy, transplanted within two weeks of LVAD implantation and bridged to transplantation before 2003 as opposed to patients transplanted more recently. Based on the available evidence we conclude that in selected patients survival after heart transplantation in patients bridged with VAD is comparable to those who did not receive the device.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS [1] .
Clinical scenario
You have just had an offer of a heart and you are looking down a list of potential recipients with a colleague. There is only a choice of two, a 65-year-old with ischaemic cardiomyopathy or a 30-year-old with a left ventricular assist device (LVAD). You are keen to take on the patient with the LVAD, but your colleague says that this is much higher risk than the 65-year-old and he has suffered several poor outcomes with LVAD explantations to transplant. You are surprised at this and resolve to check the current status of this operation in the literature.
Three-part question
[In patients undergoing heart transplantation] are [patients with a prior left ventricular assist device (LVAD)] at higher risk for [mortality or additional morbidity]?
Search strategy
Medline search from 1996 to March Week 4 2011 was performed using OVID interface: (ventricular assist device/ OR mechanical circulatory support.mp. OR LVAD.mp.) AND (bridge to transplant$.mp.).
Search outcome
Four hundred and twenty-eight papers were found using the reported search. From these 12 papers were identified that provided the best evidence. These are presented in Table 1 .
Results
Massad et al. [2] transplantation with ventricular assist device (VAD) had a different outcome than patients who underwent transplantation without a bridge. They retrospectively analyzed 53 patients who received Heart Mate I and 203 patients with no support. One year survival was 94% in the LVAD group and 88% in the control group (difference not significant).
Sinha et al. [3] conducted a retrospective study comparing post-transplant outcome in 61 patients bridged with LVAD with 50 controls without mechanical support. They did not find any difference in three-year survival.
Jaski et al. [4] reviewed 5880 transplanted patients. Of these, 409 received intracorporeal, 85 extracorporeal and eight unspecified LVADs. Their analysis showed no significant difference in post-transplant survival between the LVAD and medical therapy groups.
Schmid et al. [5] reported the outcome of 41 patients bridged to transplantation with LVAD and compared their follow-up with 146 patients who underwent transplantation without prior mechanical support. Their data showed similar survival rate and comparable cardiac morbidity for both groups.
Morgan et al. [6] published their outcome of 121 mechanically supported patients and 145 patents bridged to transplantation with inotropes. Study showed that patients with mechanical support had similar post-transplantation survival with patients bridged with inotropic drugs. Gammie et al. [7] sought to determine the influence of the interval from VAD implantation to cardiac transplantation on post-transplant survival. They reported decreased survival for patients undergoing transplantation within two weeks of VAD implantation compared with those undergoing transplantation later.
Cleveland et al. [8] in their study concluded that LVADs do not compromise one-year survival after cardiac transplantation.
Osaki et al. [9] divided 531 consecutive heart transplant recipients into two study periods: January 1990 to July 2003 and August 2003 to August 2007. They compared post-transplant outcome of bridged and non-bridged patients within these two study periods. From 1990 to 2003 survival in the bridged patients was significantly worse than in the non-bridged group. However, there was no difference in survival between groups in the recent era.
Pal et al. [10] conducted a retrospective review to evaluate outcomes in United Network of Organ Sharing status 1 heart transplant recipients who were bridged to transplant with an implantable LVAD or with intravenous inotropes. They concluded that short-term and long-term survival and morbidity after transplantation is similar with LVAD bridging compared with inotropic bridging.
Russo et al. [11] compared post-transplantation survival in non-bridged transplant recipients with survival of recipients bridged to transplant with extracorporeal, paracorporeal, and intracorporeal VADs. They reported that both intracorporeal and paracorporeal devices are not associated with diminished post-transplant survival. However, 90-day survival was diminished in recipients bridged with extracorporeal devices. Furthermore, risk-adjusted survival at more than five years was better in the intracorporeal group than the non-bridged group.
Patlolla et al. [12] compared 9455 patients who underwent first-time, single-organ heart transplantation with the outcome of 1433 patients bridged with intracorporeal and 448 extracorporeal VADs. They concluded that extracorporeal VADs are associated with higher mortality within six months and again five years after transplantation. Intracorporeal VADs are associated with a small increase in mortality in the first six months and a clinically significant increase in mortality beyond five years.
Bull et al. [13] focused their analysis on two most common causes of end-stage heart failure requiring transplantation: idiopathic dilated cardiomyopathy (n=201) and coronary artery disease (n=213). VADs were placed as a bridge to transplant in 110 patients. In patients with idiopathic dilated cardiomyopathy survival was decreased at one year and five years, but not at 10 years post-transplant. In patients with coronary artery disease, the use of VAD as a bridge to transplant did not influence survival at one, five, and 10 years post-transplant.
Clinical bottom line
The effect of VAD bridging on post-transplant outcomes remains controversial. Experienced centers have shown outstanding post-transplant results with LVAD bridging. Conversely, large registries continue to identify LVAD bridging as a predictor of reduced survival after transplantation. Major limitation of these studies is the fact, that they do not assess the effect of VADs on survival to transplant and only assess their effect post-transplant. One therefore, cannot estimate the overall benefit or harm of VADs. Factors influencing the outcome of patients bridged to transplantation include etiology of heart failure, time period of implantation, type of device used and interval from VAD implantation to transplantation. Better outcomes are reported for patients with ischemic heart failure, bridged in recent era with secondgeneration axial-flow devices, who are transplanted more than 30 days from VAD implantation. Technological advances in VAD design as well as improvements in peri-and postoperative management have resulted in comparable post-transplant survival of bridged and non-bridged patients.
